Skip to main content

Table 1 Demographics and baseline clinical characteristics of the patients and clinical samples

From: Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia

PatientsNumber (%) (n = 85)Median [IQR]
 Age (years) 64 [54–69]
 Male62 (73) 
 Co-morbid conditions
  Heart transplant10 (12) 
  Lung transplant10 (12) 
  COPD14 (16) 
  Active chemotherapy for cancer*6 (7) 
  AIDS5 (6) 
  Chronic dialysis3 (4) 
Clinical samplesNumber (%) (n = 95)Median [IQR]
 Pneumonia
  Ventilator-associated71 (75) 
  Ventilated hospital-acquired24 (25) 
 Severity of disease
  Days in intensive care 5.6 [3.5–14]
  SAPS II score 59 [36–72]
  Days of mechanical ventilation 5.5 [3.4–11]
  Relapse of pneumonia24 (25) 
  Deaths30 (32) 
 Laboratory
  ESBL carrier23 (24) 
  MRSA carrier1 (1) 
 Antibiotics in the 7 days before the episode of pneumonia**41 (43) 
  Cefotaxime11 (12) 
  Piperacillin-tazobactam7 (7) 
  Amikacin7 (7) 
  Cefepime6 (6) 
  Metronidazole5 (5) 
 Sampling
  Bronchoalveolar lavage72 (76) 
  Plugged telescoping catheter23 (24) 
 Turnaround time of Unyvero HPN (hours) 4.6 [4.4–5]
  Lysis 0.5 [0.5–0.5
  Waiting time 0.1 [0.1–0.4]
  Analysis 3.8 [3.8–3.8]
  1. *Three patients with lung cancer, 2 with esophagus cancer, and one with melanoma
  2. **Only the 5 most frequently prescribed antibiotics are reported